Research ExplorerPublicationsTranscriptome Guided Drug Combination Suppresses Proliferati...

Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells

Standard

Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells. / Shkurnikov, M Yu; Poloznikov, A A; Nikulin, S V; Schumacher, U; Wicklein, D; Stürken, C; Galatenko, V V; Alekseev, B Ya.

In: B EXP BIOL MED+, Vol. 166, No. 5, 03.2019, p. 656-660.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Shkurnikov, MY, Poloznikov, AA, Nikulin, SV, Schumacher, U, Wicklein, D, Stürken, C, Galatenko, VV & Alekseev, BY 2019, 'Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells', B EXP BIOL MED+, vol. 166, no. 5, pp. 656-660. https://doi.org/10.1007/s10517-019-04412-4

APA

Shkurnikov, M. Y., Poloznikov, A. A., Nikulin, S. V., Schumacher, U., Wicklein, D., Stürken, C., Galatenko, V. V., & Alekseev, B. Y. (2019). Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells. B EXP BIOL MED+, 166(5), 656-660. https://doi.org/10.1007/s10517-019-04412-4

Vancouver

Shkurnikov MY, Poloznikov AA, Nikulin SV, Schumacher U, Wicklein D, Stürken C et al. Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells. B EXP BIOL MED+. 2019 Mar;166(5):656-660. https://doi.org/10.1007/s10517-019-04412-4

Bibtex

@article{1985ae1412c04e879be269398cb07af1,
title = "Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells",
abstract = "One of actively developing trends in modern pharmacology is the use of the transcriptome analysis for drug repositioning. We have previously detected two molecular markers of relapses in patients with malignant breast tumors: ELOVL5 and IGFBP6. Poor prognosis is associated with low expression of these markers. Here we analyze the effects of simvastatin and a new potential proteasome inhibitor K7174 inducing expression of IGFBP6 and EVOVL5 on the proliferation of breast cancer cells MDA-MB-231 and DU4475. Compound K7174 potentiates the inhibitory effect of simvastatin on the proliferation of DU4475 cells characterized by low expression of ELOVL5-IGFBP6 pair, but not on the proliferation of MDA-MB-231 cells with high expression of these markers.",
keywords = "Journal Article",
author = "Shkurnikov, {M Yu} and Poloznikov, {A A} and Nikulin, {S V} and U Schumacher and D Wicklein and C St{\"u}rken and Galatenko, {V V} and Alekseev, {B Ya}",
year = "2019",
month = mar,
doi = "10.1007/s10517-019-04412-4",
language = "English",
volume = "166",
pages = "656--660",
journal = "B EXP BIOL MED+",
issn = "0007-4888",
publisher = "Springer New York",
number = "5",

}

RIS

TY - JOUR

T1 - Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells

AU - Shkurnikov, M Yu

AU - Poloznikov, A A

AU - Nikulin, S V

AU - Schumacher, U

AU - Wicklein, D

AU - Stürken, C

AU - Galatenko, V V

AU - Alekseev, B Ya

PY - 2019/3

Y1 - 2019/3

N2 - One of actively developing trends in modern pharmacology is the use of the transcriptome analysis for drug repositioning. We have previously detected two molecular markers of relapses in patients with malignant breast tumors: ELOVL5 and IGFBP6. Poor prognosis is associated with low expression of these markers. Here we analyze the effects of simvastatin and a new potential proteasome inhibitor K7174 inducing expression of IGFBP6 and EVOVL5 on the proliferation of breast cancer cells MDA-MB-231 and DU4475. Compound K7174 potentiates the inhibitory effect of simvastatin on the proliferation of DU4475 cells characterized by low expression of ELOVL5-IGFBP6 pair, but not on the proliferation of MDA-MB-231 cells with high expression of these markers.

AB - One of actively developing trends in modern pharmacology is the use of the transcriptome analysis for drug repositioning. We have previously detected two molecular markers of relapses in patients with malignant breast tumors: ELOVL5 and IGFBP6. Poor prognosis is associated with low expression of these markers. Here we analyze the effects of simvastatin and a new potential proteasome inhibitor K7174 inducing expression of IGFBP6 and EVOVL5 on the proliferation of breast cancer cells MDA-MB-231 and DU4475. Compound K7174 potentiates the inhibitory effect of simvastatin on the proliferation of DU4475 cells characterized by low expression of ELOVL5-IGFBP6 pair, but not on the proliferation of MDA-MB-231 cells with high expression of these markers.

KW - Journal Article

U2 - 10.1007/s10517-019-04412-4

DO - 10.1007/s10517-019-04412-4

M3 - SCORING: Journal article

C2 - 30903492

VL - 166

SP - 656

EP - 660

JO - B EXP BIOL MED+

JF - B EXP BIOL MED+

SN - 0007-4888

IS - 5

ER -